检索结果 - Marissa N. Balak

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas

    Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas 由 Yixuan Gong, Romel Somwar, Katerina Politi, Marissa N. Balak, Juliann Chmielecki, Xuejun Jiang, William Pao

    出版 2007
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with <i>EGFR</i>-Mutant Lung Adenocarcinoma

    Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with <i>EGFR</i>-Mutant Lung Adenocarcinoma 由 James Bean, Gregory J. Riely, Marissa N. Balak, Jenifer L. Marks, Marc Ladanyi, Vincent A. Miller, William Pao

    出版 2008
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase Inhibitors

    Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase Inhibitors 由 Lucía Regales, Marissa N. Balak, Yixuan Gong, Katerina Politi, Ayana Sawai, Carl Le, Jason A. Koutcher, David B. Solit, Neal Rosen, Maureen F. Zakowski, William Pao

    出版 2007
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

    Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors 由 Marissa N. Balak, Yixuan Gong, Gregory J. Riely, Romel Somwar, Allan R. Li, Maureen F. Zakowski, Anne C. Chiang, Guangli Yang, Ouathek Ouerfelli, Mark G. Kris, Marc Ladanyi, Vincent A. Miller, William Pao

    出版 2006
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus

    Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus 由 Hung Huynh, Huai-Xiang Hao, Stephen L. Chan, David Chen, Richard Ong, Khee Chee Soo, Panisa Pochanard, David T. Yang, David A. Ruddy, Manway Liu, Adnan Derti, Marissa N. Balak, Michael R. Palmer, Yan Wang, Benjamin H. Lee, Dalila Sellami, Andrew X. Zhu, Robert Schlegel, Alan Huang

    出版 2015
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    <i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib

    <i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib 由 James Bean, Cameron Brennan, Jin‐Yuan Shih, Gregory J. Riely, Agnès Viale, Lu Wang, Dhananjay Chitale, Noriko Motoi, János Szőke, Stephen Broderick, Marissa N. Balak, W.C. Chang, Chong‐Jen Yu, Adi F. Gazdar, Harvey I. Pass, Valerie W. Rusch, William L. Gerald, Shiu‐Feng Huang, Pan‐Chyr Yang, Vincent A. Miller, Marc Ladanyi, James Chih‐Hsin Yang, William Pao

    出版 2007
    获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: